-

World’s First aprevo™ Personalized Spine Surgery Performed Using the Only Available Spine Technology with FDA Breakthrough Designation

SAN DIEGO--(BUSINESS WIRE)--Carlsmed, Inc. is announcing today that the first aprevo patient specific spinal surgery has been successfully performed. Christopher Ames, M.D., director of spinal tumor and spinal deformity surgery at UC San Francisco Medical Center, assisted by Patrick Maloney, M.D., performed this landmark surgical procedure.

“Carlsmed’s aprevo family of devices represent a new generation of surgical implants that are individualized to each patient,” said Mike Cordonnier, CEO of Carlsmed. “This approach to precision medicine gives surgeons, patients, and hospitals confidence that each surgical treatment has been digitally optimized for patient outcomes before stepping into the operating room.”

Cordonnier continued, “With the advent of Carlsmed’s digital to device technology, there is no longer a need for hospitals to manage the complex inventory logistics of traditional surgical implants. The aprevo family of patient specific devices eliminate the tedious and costly process of stock device inventory control and reprocessing.” Carlsmed uses data to create spine fusion devices that are specifically designed and manufactured for each patient and UCSF is the first institution in the world to offer this technology to patients.

About Carlsmed

Carlsmed is personalizing devices for the treatment of complex adult spinal deformities. The Company uses data to create surgical plans and aprevo devices tailored to the precise medical situation of each patient. Our mission is to transform healthcare by finally giving spine surgeons the tools to obtain better results at a lower cost of treatment while helping adults regain their active lifestyles. For more information, visit www.carlsmed.com or contact us at info@carlsmed.com.

Contacts

Carolyn Holck
carolyn@carlsmed.com

Carlsmed, Inc. Logo
Carlsmed, Inc. Logo

Carlsmed, Inc.


Release Summary
Carlsmed announced world’s first aprevo™ personalized spine surgery performed.
Release Versions

Contacts

Carolyn Holck
carolyn@carlsmed.com

Social Media Profiles
More News From Carlsmed, Inc.

Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing patient-specific spine surgery solutions that enhance outcomes and surgical precision. The FDA previously granted Breakthrough Device designation for Carlsmed’s aprevo® technology for the treatment of pat...

Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver its aprevo® personalized spinal fusion implants to hospitals in less than ten days. “This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The re...

Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ). In addition to Carlsmed, he currently serves on the board of Nevro (NVRO). Mr. O’Boyle has over 20 years of executive management exp...
Back to Newsroom